Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy, analysts say.
Britain's second biggest drug maker apparently outbid Switzerland's Actelion Pharmaceuticals Ltd. to buy ZS Pharma Inc., a victory that brings...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
